Immunology of Multiple Sclerosis

Seminars in Neurology

Volumn 36, Issue 2, 2016, Pages 115-127

  Sospedra, Mireia ^a   Martin, Roland ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

adaptive immunity; antibodies; B cells; immunology; multiple sclerosis; pathomechanisms; T cells

Indexed keywords

ANTIBODY; HLA DR ANTIGEN; HLA-DR15 ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; AXON; B LYMPHOCYTE; CELL MIGRATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVE DEGENERATION; NEUROIMMUNOLOGY; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE INJURY; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; GENETICS; IMMUNOLOGY; INFLAMMATION;

AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; HLA-DR SEROLOGICAL SUBTYPES; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 84988431124     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0036-1579739     Document Type: Article

References (192)

1. Orton S. M., Herrera B. M., Yee I. M., et al. Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol: 2006; 5 11 932 936
2. Compston A., Coles A. Multiple sclerosis. Lancet: 2008; 372 9648 1502 1517
3. Sawcer S., Hellenthal G., Pirinen M., et al. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature: 2011; 476 7359 214 219
4. Beecham A. H., Patsopoulos N. A., Xifara D. K., et al. International Multiple Sclerosis Genetics Consortium (IMSGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet: 2013; 45 11 1353 1360
5. Ascherio A., Munger K. L., Lünemann J. D. The initiation and prevention of multiple sclerosis. Nat Rev Neurol: 2012; 8 11 602 612
6. Coles A. J., Wing M. G., Molyneux P., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol: 1999; 46 3 296 304
7. Molyneux P. D., Kappos L., Polman C., et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain: 2000; 123 (Pt 11): 2256 2263
8. Filippi M., Rovaris M., Rice G. P., et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci: 2000; 176 1 42 44
9. Feinstein A., Freeman J., Lo A. C. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol: 2015; 14 2 194 207
10. Bielekova B., Kadom N., Fisher E., et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology: 2005; 65 7 1071 1076
11. Filippi M., Rocca M. A. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol: 2005; 252 05 v16 v24
12. Anderson V. M., Fox N. C., Miller D. H. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging: 2006; 23 5 605 618
13. Zivadinov R., Cox J. L. Neuroimaging in multiple sclerosis. Int Rev Neurobiol: 2007; 79 449 474
14. Frischer J. M., Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain: 2009; 132 (Pt 5): 1175 1189
15. Bjartmar C., Kinkel R. P., Kidd G., Rudick R. A., Trapp B. D. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology: 2001; 57 7 1248 1252
16. DeLuca G. C., Williams K., Evangelou N., Ebers G. C., Esiri M. M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain: 2006; 129 (Pt 6): 1507 1516
17. Kornek B., Storch M. K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol: 2000; 157 1 267 276
18. Peterson J. W., Bö L., Mörk S., Chang A., Trapp B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol: 2001; 50 3 389 400
19. Bo L., Vedeler C. A., Nyland H., Trapp B. D., Mork S. J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler: 2003; 9 4 323 331
20. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med: 1998; 338 5 278 285
21. Chard D. T., Griffin C. M., Parker G. J., Kapoor R., Thompson A. J., Miller D. H. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain: 2002; 125 (Pt 2): 327 337
22. Miller D. H., Barkhof F., Frank J. A., Parker G. J., Thompson A. J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain: 2002; 125 (Pt 8): 1676 1695
23. Young K. L., Brandt A. U., Petzold A., et al. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. Eur J Neurol: 2013; 20 5 803 811
24. Kuhle J., Leppert D., Petzold A., et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology: 2011; 76 14 1206 1213
25. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol: 2000; 47 6 707 717
26. Metz I., Weigand S. D., Popescu B. F., et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol: 2014; 75 5 728 738
27. Barnett M. H., Prineas J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol: 2004; 55 4 458 468
28. Breij E. C., Brink B. P., Veerhuis R., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol: 2008; 63 1 16 25
29. Mahad D. J., Trebst C., Kivisäkk P., et al. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropathol Exp Neurol: 2004; 63 3 262 273
30. Keegan M., König F., McClelland R., et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet: 2005; 366 9485 579 582
31. Quintana F. J., Farez M. F., Viglietta V., et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A: 2008; 105 48 18889 18894
32. Planas R., Metz I., Ortiz Y., et al. Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions. Ann Clin Transl Neurol: 2015; 2 9 875 893
33. Mokhtarian F., McFarlin D. E., Raine C. S. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature: 1984; 309 5966 356 358
34. Zamvil S. S., Mitchell D. J., Moore A. C., Kitamura K., Steinman L., Rothbard J. B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature: 1986; 324 6094 258 260
35. Tuohy V. K., Sobel R. A., Lees M. B. Susceptibility to PLP-induced EAE is regulated by non-H-2 genes. Ann N Y Acad Sci: 1988; 540 709 711
36. Mendel I., Kerlero de Rosbo N., Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol: 1995; 25 7 1951 1959
37. Kojima K., Berger T., Lassmann H., et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med: 1994; 180 3 817 829
38. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu Rev Immunol: 1992; 10 153 187
39. Ben-Nun A., Wekerle H., Cohen I. R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol: 1981; 11 3 195 199
40. Pettinelli C. B., McFarlin D. E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol: 1981; 127 4 1420 1423
41. Madsen L. S., Andersson E. C., Jansson L., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet: 1999; 23 3 343 347
42. Quandt J. A., Huh J., Baig M., et al. Myelin basic protein-specific TCR/HLA-DRB5∗01:01 transgenic mice support the etiologic role of DRB5∗01:01 in multiple sclerosis. J Immunol: 2012; 189 6 2897 2908
43. Quandt J. A., Baig M., Yao K., et al. Unique clinical and pathological features in HLA-DRB1∗0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med: 2004; 200 2 223 234
44. Hafler D. A., Compston A., Sawcer S., et al. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med: 2007; 357 9 851 862
45. Berer K., Mues M., Koutrolos M., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature: 2011; 479 7374 538 541
46. Odoardi F., Sie C., Streyl K., et al. T cells become licensed in the lung to enter the central nervous system. Nature: 2012; 488 7413 675 679
47. Wekerle H., Berer K., Krishnamoorthy G. Remote control-triggering of brain autoimmune disease in the gut. Curr Opin Immunol: 2013; 25 6 683 689
48. Hedström A. K., Bäärnhielm M., Olsson T., Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology: 2009; 73 9 696 701
49. Kleinewietfeld M., Manzel A., Titze J., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature: 2013; 496 7446 518 522
50. Ransohoff R. M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol: 2012; 12 9 623 635
51. Fujinami R. S., Oldstone M. B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science: 1985; 230 4729 1043 1045
52. Gran B., Hemmer B., Vergelli M., McFarland H. F., Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol: 1999; 45 5 559 567
53. Wucherpfennig K. W., Strominger J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell: 1995; 80 5 695 705
54. Hemmer B., Fleckenstein B. T., Vergelli M., et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med: 1997; 185 9 1651 1659
55. Hemmer B., Gran B., Zhao Y., et al. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med: 1999; 5 12 1375 1382
56. Lang H. L., Jacobsen H., Ikemizu S., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol: 2002; 3 10 940 943
57. Sospedra M., Muraro P. A., Stefanová I., et al. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol: 2006; 176 3 1951 1961
58. Yousef S., Planas R., Chakroun K., et al. TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. J Immunol: 2012; 189 7 3618 3630
59. Sibley W. A., Bamford C. R., Clark K. Clinical viral infections and multiple sclerosis. Lancet: 1985; 1 8441 1313 1315
60. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol: 2005; 23 683 747
61. Cao Y., Goods B. A., Raddassi K., et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med: 2015; 7 287 287ra74
62. Markovic-Plese S., Cortese I., Wandinger K. P., McFarland H. F., Martin R. CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest: 2001; 108 8 1185 1194
63. Lassmann H., Ransohoff R. M. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol: 2004; 25 3 132 137
64. Trotter J. L., Damico C. A., Cross A. H., et al. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol: 1997; 75 1-2 95 103
65. Bielekova B., Sung M. H., Kadom N., Simon R., McFarland H., Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol: 2004; 172 6 3893 3904
66. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med: 2000; 6 10 1167 1175
67. Muraro P. A., Wandinger K. P., Bielekova B., et al. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain: 2003; 126 Pt 1 20 31
68. Link J., Lorentzen A. R., Kockum I., et al. Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol: 2010; 226 1-2 172 176
69. Healy B. C., Liguori M., Tran D., et al. HLA B∗44: protective effects in MS susceptibility and MRI outcome measures. Neurology: 2010; 75 7 634 640
70. Friese M. A., Jakobsen K. B., Friis L., et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med: 2008; 14 11 1227 1235
71. MacNamara K. C., Bender S. J., Chua M. M., Watson R., Weiss S. R. Priming of CD8+ T cells during central nervous system infection with a murine coronavirus is strain dependent. J Virol: 2008; 82 13 6150 6160
72. Hauser S. L., Bhan A. K., Gilles F., Kemp M., Kerr C., Weiner H. L. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol: 1986; 19 6 578 587
73. Babbe H., Roers A., Waisman A., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med: 2000; 192 3 393 404
74. Skulina C., Schmidt S., Dornmair K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A: 2004; 101 8 2428 2433
75. Junker A., Ivanidze J., Malotka J., et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain: 2007; 130 (Pt 11): 2789 2799
76. Neumann H., Cavalié A., Jenne D. E., Wekerle H. Induction of MHC class I genes in neurons. Science: 1995; 269 5223 549 552
77. Yshii L., Gebauer C., Bernard-Valnet R., Liblau R. Neurons and T cells: Understanding this interaction for inflammatory neurological diseases. Eur J Immunol: 2015; 45 10 2712 2720
78. Olsson T., Wallström E. IFN-secreting cells. Neurology: 1996; 47 3 854 855
79. Harrington L. E., Hatton R. D., Mangan P. R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol: 2005; 6 11 1123 1132
80. Park H., Li Z., Yang X. O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol: 2005; 6 11 1133 1141
81. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol: 2012; 33 10 505 512
82. Codarri L., Gyülvészi G., Tosevski V., et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol: 2011; 12 6 560 567
83. Korn T., Bettelli E., Oukka M., Kuchroo V. K. IL-17 and Th17 cells. Annu Rev Immunol: 2009; 27 485 517
84. Steinman L. A rush to judgment on Th17. J Exp Med: 2008; 205 7 1517 1522
85. Kebir H., Kreymborg K., Ifergan I., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med: 2007; 13 10 1173 1175
86. Tzartos J. S., Friese M. A., Craner M. J., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol: 2008; 172 1 146 155
87. Lock C., Hermans G., Pedotti R., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med: 2002; 8 5 500 508
88. + T cell clones primed by pathogens or vaccines. Science: 2015; 347 6220 400 406
89. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet: 2009; 41 7 824 828
90. De Jager P. L., Jia X., Wang J., et al. International MS Genetics Consortium. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet: 2009; 41 7 776 782
91. Burton P. R., Clayton D. G., Cardon L. R., et al. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC); Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee; Breast Cancer Susceptibility Collaboration (UK). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet: 2007; 39 11 1329 1337
92. Gregory S. G., Schmidt S., Seth P., et al. Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet: 2007; 39 9 1083 1091
93. McKay F. C., Swain L. I., Schibeci S. D., et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun: 2008; 9 1 1 6
94. Jäger J., Schulze C., Rösner S., Martin R. IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. Genes Immun: 2013; 14 7 453 461
95. Yang L., Anderson D. E., Kuchroo J., Hafler D. A. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol: 2008; 180 7 4409 4414
96. Koguchi K., Anderson D. E., Yang L., O'Connor K. C., Kuchroo V. K., Hafler D. A. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med: 2006; 203 6 1413 1418
97. Stürner K. H., Borgmeyer U., Schulze C., Pless O., Martin R. A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function. J Immunol: 2014; 193 9 4439 4447
98. Hoppmann N., Graetz C., Paterka M., et al. New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain: 2015; 138 (Pt 4): 902 917
99. Viglietta V., Baecher-Allan C., Weiner H. L., Hafler D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med: 2004; 199 7 971 979
100. Haas J., Hug A., Viehöver A., et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol: 2005; 35 11 3343 3352
101. Dominguez-Villar M., Baecher-Allan C. M., Hafler D. A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med: 2011; 17 6 673 675
102. Baecher-Allan C. M., Costantino C. M., Cvetanovich G. L., et al. CD2 costimulation reveals defective activity by human CD4+CD25(hi) regulatory cells in patients with multiple sclerosis. J Immunol: 2011; 186 6 3317 3326
103. Zheng Y., Josefowicz S. Z., Kas A., Chu T. T., Gavin M. A., Rudensky A. Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature: 2007; 445 7130 936 940
104. Marson A., Kretschmer K., Frampton G. M., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature: 2007; 445 7130 931 935
105. Housley W. J., Fernandez S. D., Vera K., et al. Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med: 2015; 7 291 291ra93
106. Rumble J. M., Huber A. K., Krishnamoorthy G., et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med: 2015; 212 1 23 35
107. Naegele M., Tillack K., Reinhardt S., Schippling S., Martin R., Sospedra M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol: 2012; 242 1-2 60 71
108. Openshaw H., Stuve O., Antel J. P., et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology: 2000; 54 11 2147 2150
109. Tillack K., Breiden P., Martin R., Sospedra M. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol: 2012; 188 7 3150 3159
110. Illés Z., Kondo T., Newcombe J., Oka N., Tabira T., Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol: 2000; 164 8 4375 4381
111. Gately C. M., Podbielska M., Counihan T., et al. Invariant natural killer T-cell anergy to endogenous myelin acetyl-glycolipids in multiple sclerosis. J Neuroimmunol: 2013; 259 1-2 1 7
112. Annibali V., Ristori G., Angelini D. F., et al. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain: 2011; 134 (Pt 2): 542 554
113. Abrahamsson S. V., Angelini D. F., Dubinsky A. N., et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain: 2013; 136 (Pt 9): 2888 2903
114. + MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J Immunol: 2014; 44 10 3119 3128
115. Held K., Beltrán E., Moser M., Hohlfeld R., Dornmair K. T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis. Hum Immunol: 2015; 76 9 607 614
116. Kastrukoff L. F., Morgan N. G., Zecchini D., et al. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol: 1998; 86 2 123 133
117. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A: 2004; 101 23 8705 8708
118. Bielekova B., Catalfamo M., Reichert-Scrivner S., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A: 2006; 103 15 5941 5946
119. Kabat E. A., Moore D. H., Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest: 1942; 21 5 571 577
120. Berger T., Rubner P., Schautzer F., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med: 2003; 349 2 139 145
121. Pröbstel A. K., Dornmair K., Bittner R., et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology: 2011; 77 6 580 588
122. Rostasy K., Mader S., Schanda K., et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol: 2012; 69 6 752 756
123. Nakajima H., Motomura M., Tanaka K., et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open: 2015; 5 4 e007766
124. Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol: 2012; 8 11 613 623
125. Srivastava R., Aslam M., Kalluri S. R., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med: 2012; 367 2 115 123
126. Mathey E. K., Derfuss T., Storch M. K., et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med: 2007; 204 10 2363 2372
127. Derfuss T., Parikh K., Velhin S., et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A: 2009; 106 20 8302 8307
128. Elliott C., Lindner M., Arthur A., et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain: 2012; 135 (Pt 6): 1819 1833
129. Stefferl A., Brehm U., Linington C. The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl: 2000; 58 58 123 133
130. Villar L. M., Sádaba M. C., Roldán E., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest: 2005; 115 1 187 194
131. Magliozzi R., Howell O., Vora A., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain: 2007; 130 (Pt 4): 1089 1104
132. Salvetti M., Giovannoni G., Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol: 2009; 22 3 201 206
133. Serafini B., Rosicarelli B., Franciotta D., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med: 2007; 204 12 2899 2912
134. Serafini B., Muzio L., Rosicarelli B., Aloisi F. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain: 2013; 136 (Pt 7): e233
135. Lassmann H., Niedobitek G., Aloisi F., Middeldorp J. M.; NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain: 2011; 134 (Pt 9): 2772 2786
136. Howell O. W., Reeves C. A., Nicholas R., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain: 2011; 134 (Pt 9): 2755 2771
137. Gardner C., Magliozzi R., Durrenberger P. F., Howell O. W., Rundle J., Reynolds R. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain: 2013; 136 (Pt 12): 3596 3608
138. Stern J. N., Yaari G., Vander Heiden J. A., et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med: 2014; 6 248 248ra107
139. von Büdingen H. C., Kuo T. C., Sirota M., et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest: 2012; 122 12 4533 4543
140. Palanichamy A., Apeltsin L., Kuo T. C., et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med: 2014; 6 248 248ra106
141. Hauser S. L., Waubant E., Arnold D. L., et al. HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med: 2008; 358 7 676 688
142. Hauser S. L., Comi G. C., Hartung H. P., et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double-blind, phase III OPERA I and II studies. ECTRIMS Online Library 2015; 116634
143. Lutterotti A., Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol: 2008; 7 6 538 547
144. Li R., Rezk A., Miyazaki Y., et al. Canadian B cells in MS Team. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med: 2015; 7 310 310ra166
145. Dang V. D., Hilgenberg E., Ries S., Shen P., Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol: 2014; 28 77 83
146. Engelhardt B., Ransohoff R. M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol: 2012; 33 12 579 589
147. Kivisäkk P., Mahad D. J., Callahan M. K., et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A: 2003; 100 14 8389 8394
148. Kivisäkk P., Imitola J., Rasmussen S., et al. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol: 2009; 65 4 457 469
149. Greter M., Heppner F. L., Lemos M. P., et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med: 2005; 11 3 328 334
150. Heppner F. L., Greter M., Marino D., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med: 2005; 11 2 146 152
151. Brown D. A., Sawchenko P. E. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol: 2007; 502 2 236 260
152. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature: 1992; 356 6364 63 66
153. Engelhardt B., Briskin M. J. Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol: 2005; 35 8 2268 2273
154. Khatri B. O., Man S., Giovannoni G., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology: 2009; 72 5 402 409
155. Man S., Tucky B., Bagheri N., Li X., Kochar R., Ransohoff R. M. Alpha4 integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J Neuroimmunol: 2009; 210 1-2 92 99
156. Coisne C., Mao W., Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol: 2009; 182 10 5909 5913
157. Ransohoff R. M. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity: 2009; 31 5 711 721
158. Reboldi A., Coisne C., Baumjohann D., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol: 2009; 10 5 514 523
159. Rothhammer V., Heink S., Petermann F., et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med: 2011; 208 12 2465 2476
160. Kawakami N., Lassmann S., Li Z., et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med: 2004; 199 2 185 197
161. Bartholomäus I., Kawakami N., Odoardi F., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature: 2009; 462 7269 94 98
162. Schreiber T. H., Shinder V., Cain D. W., Alon R., Sackstein R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood: 2007; 109 4 1381 1386
163. Kim J. V., Kang S. S., Dustin M. L., McGavern D. B. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature: 2009; 457 7226 191 195
164. Ferguson B., Matyszak M. K., Esiri M. M., Perry V. H. Axonal damage in acute multiple sclerosis lesions. Brain: 1997; 120 (Pt 3): 393 399
165. Vergelli M., Le H., van Noort J. M., Dhib-Jalbut S., McFarland H., Martin R. A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J Immunol: 1996; 157 2 679 688
166. Vergelli M., Hemmer B., Muraro P. A., et al. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol: 1997; 158 6 2756 2761
167. Antel J. P., McCrea E., Ladiwala U., Qin Y. F., Becher B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J Immunol: 1998; 160 4 1606 1611
168. Zaguia F., Saikali P., Ludwin S., et al. Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. J Immunol: 2013; 190 6 2510 2518
169. Aktas O., Smorodchenko A., Brocke S., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron: 2005; 46 3 421 432
170. Jurewicz A., Matysiak M., Andrzejak S., Selmaj K. TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia: 2006; 53 2 158 166
171. Suidan H. S., Bouvier J., Schaerer E., Stone S. R., Monard D., Tschopp J. Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes. Proc Natl Acad Sci U S A: 1994; 91 17 8112 8116
172. Selmaj K. W., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol: 1988; 23 4 339 346
173. Almeida-Leite C. M., Galvão L. M., Afonso L. C., Cunha F. Q., Arantes R. M. Interferon-gamma induced nitric oxide mediates in vitro neuronal damage by Trypanosoma cruzi-infected macrophages. Neurobiol Dis: 2007; 25 1 170 178
174. Wong G., Goldshmit Y., Turnley A. M. Interferon-gamma but not TNF alpha promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells. Exp Neurol: 2004; 187 1 171 177
175. Lees J. R., Golumbek P. T., Sim J., Dorsey D., Russell J. H. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med: 2008; 205 11 2633 2642
176. Kroenke M. A., Carlson T. J., Andjelkovic A. V., Segal B. M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med: 2008; 205 7 1535 1541
177. Calabrese M., Magliozzi R., Ciccarelli O., Geurts J. J., Reynolds R., Martin R. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci: 2015; 16 3 147 158
178. Lucchinetti C. F., Popescu B. F., Bunyan R. F., et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med: 2011; 365 23 2188 2197
179. Zeis T., Graumann U., Reynolds R., Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain: 2008; 131 (Pt 1): 288 303
180. Graumann U., Reynolds R., Steck A. J., Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol: 2003; 13 4 554 573
181. Brück W., Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol: 2005; 18 3 221 224
182. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci: 2013; 333 1-2 1 4
183. Mahad D. H., Trapp B. D., Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol: 2015; 14 2 183 193
184. Astier A. L., Meiffren G., Freeman S., Hafler D. A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest: 2006; 116 12 3252 3257
185. Venken K., Hellings N., Hensen K., et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res: 2006; 83 8 1432 1446
186. Venken K., Hellings N., Broekmans T., Hensen K., Rummens J. L., Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol: 2008; 180 9 6411 6420
187. McKay F. C., Swain L. I., Schibeci S. D., et al. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. J Autoimmun: 2008; 31 1 52 58
188. Nyirenda M. H., Morandi E., Vinkemeier U., et al. TLR2 stimulation regulates the balance between regulatory T cell and Th17 function: a novel mechanism of reduced regulatory T cell function in multiple sclerosis. J Immunol: 2015; 194 12 5761 5774
189. Farez M. F., Mascanfroni I. D., Méndez-Huergo S. P., et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell: 2015; 162 6 1338 1352
190. Kappos L., Wiendl H., Selmaj K., et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med: 2015; 373 15 1418 1428
191. Bielekova B., Howard T., Packer A. N., et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol: 2009; 66 4 483 489
192. Linker R., Gold R., Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol: 2009; 29 1 43 68